Imfinzi combo drug Imjudo can be prescribed at hospitals
By Eo, Yun-Ho | translator Alice Kang
24.11.13 05:43:09
가나다라
0
Passes drug committees of SNUH, AMC, etc.
Is expected to be reviewed by CDDC after applying for reimbursement listing in June
According to industry sources, AstraZeneca Korea's CTLA-4 inhibitor Imjudo (tremelimumab) has passed the drug committees (DCs) of tertiary hospitals in Korea including Seoul National University Hospital and Seoul Asan Medical Center.
For now, however, Imjudo is a non-reimbursed drug. AstraZeneca submitted an application for the reimbursement of the PD-L1 inhibitor Imfinzi (durvalumab) and Imjudo combination for liver cancer in June and is currently awaiting a review by the Health and Insurance Review and Assessment Service’s Cancer Disease Review Committee.
Imjud
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)